Arizona Alzheimer's Disease Research Center (ADRC)

Alzheimer Disease Clinical Trial

Official title:

Arizona Alzheimer's Disease Research Center (ADRC)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05405075
• Other study ID #: ADRC-001
• Status: Recruiting
• Start date: October 1, 2021
• Est. completion date: June 30, 2026

Study information

• Verified date: July 2023
• Source: Banner Health
• Contact: Trisha Walsh
• Phone: 602.839.6029
• Email: Trisha.Walsh[@]bannerhealth.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The Arizona Alzheimer's Disease Research Center (ADRC) is the National Institute on Aging's (NIA's) first statewide AD Center (ADC), the only ADC in the Southwestern United States, and a leading example of statewide collaboration in biomedical research. It capitalizes on Arizona's strengths in brain imaging, genomics, computer science and biomathematics, the basic, cognitive and behavioral neurosciences, clinical, and neuropathological studies of AD, the discovery and evaluation of investigational treatments, and the study of normal cognitive aging.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 550
• Est. completion date: June 30, 2026
• Est. primary completion date: June 30, 2026
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Cognitively normal persons, individuals with mild cognitive impairment or dementia who are at least 40 years of age.
• Willing to undergo health and cognitive assessments, and collection and banking of blood with venipuncture for genetic research, biomarker research, and DNA banking.

Exclusion Criteria:

• 1. Participants whose diagnosis is unclear and confounded by multiple possible factors are excluded. Participants with diagnoses of non-AD dementias are not excluded.

2. Participants whose primary diagnosis is cognitive impairment due to a penetrating or single severe closed head injury, multiple sclerosis, brain tumor, metabolic or toxic encephalopathy, post-infectious (e.g., viral encephalitis, bacterial meningitis), paraneoplastic, primary psychiatric illness, or otherwise not deemed relevant to the intent of the Alzheimer Disease Center program are excluded.

3. Procedure specific exclusion criteria also apply but this does not impact the participants ability to be included in the study.

Related Conditions & MeSH terms

• Alzheimer Disease

Locations

Country	Name	City	State
United States	Banner Alzheimer's Institute	Phoenix	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Banner Health

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cognitive Status	The ADRC uses a prospective, standardized, and longitudinal clinical evaluation of participants to determine their cognitive status. This includes tests that assess short and long term memory, ability to complete daily tasks, and processing of information.	12 months